PRESS RELEASE:

Reaction Biology Receives NCI Grant Award for Epigenetic Platform

| From
drug discovery

MALVERN, Pa., Aug. 11 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC") announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot(SM) drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more. RBC's HotSpot(SM) technology is an ultra-low volume tritium-based assay platform that provides gold-standard methyltransferase inhibition data.

The technology is offered as a screening service, allowing clients to avoid operational issues related to dealing with radioisotope management, and quickly find productive lead candidates.

RBC Chief Technology Officer Haiching Ma said, "Epigenetic mechanisms are increasingly recognized as fundamental to several cancers and many other diseases. Up until now, there has been no cost-effective way to do large-scale methyltransferase screening and profiling. We hope that RBC's ability to fill this unmet need will speed the discovery of new drugs in this area."

Based in Malvern, PA, RBC specializes in providing high quality biochemical enzyme assay data, using ultra-low volumes and proprietary methods. RBC has provided its services to over 190 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.

RBC's Kinase HotSpot(SM) platform is a widely used service for providing high quality low-cost kinase screening data worldwide. The company also provides HDAC, protease, and other screening services, as well as custom assay development and partnerships.

For more information, visit: www.reactionbiology.com .

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   PIN IT   STUMBLE   LinkedIn   Instapaper   Buffer

PERMALINK:
https://www.send2press.com/newswire/2010-08-0811-003.shtml
  LEGAL NOTICE AND TERMS OF USE:  
The content of the above press release was provided by the “news source” (Reaction Biology Corporation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2010 Reaction Biology Corporation with newswire version Copr. © 2010 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Sep 27 2016:
[ count retired 8.4.16 ]


back to top
REFERENCES: drug discovery, RBC Kinase HotSpot, Reaction Biology Corporation, RBC Kinase HotSpot, HDAC, protease, and other screening services, epigenetic, methyltransferase, biotech, drug discovery, Haiching Ma, Phase II SBIR grant, National Cancer Institute, pharma, news, press release from Reaction Biology Corporation, Aug 11, 2010, Drugs and Pharmaceuticals, Pharma, , Malvern, Pennsylvania, Reaction Biology Receives NCI Grant Award for Epigenetic Platform